Pathophysiology & Clinical Findings of the Disease
1. Are the spirometry results consistent with obstructive or restrictive pulmonary disease? What is the most likely pulmonary diagnosis for this patient?
2. Explain the pathophysiology associated with the chosen pulmonary disease.
3. Identify at least three subjective findings from the case which support the chosen diagnosis.
4. Identify at least three objective findings from the case which support the chosen diagnosis
Management of the Disease
*Utilize the required Clinical Practice Guideline (CPG) to support your treatment recommendations.
1. Classify the patient’s disease severity. Is this considered stable or unstable?
2. Identify two (2) “Evidence A” recommended medication classes for the treatment of this condition and provide an example (drug name) for each.
3. Describe the mechanism of action for each of the medication classes identified above.
4. Identify two (2) “Evidence A” recommended non-pharmacological treatment options for this patient.

Sample Answer

Sample Answer

Pathophysiology and Management of Chronic Obstructive Pulmonary Disease (COPD)

Pathophysiology of COPD

Chronic Obstructive Pulmonary Disease (COPD) is characterized by airflow limitation that is not fully reversible. The most common form of COPD is a combination of chronic bronchitis and emphysema. In chronic bronchitis, there is inflammation and narrowing of the airways due to excessive mucus production, leading to cough and sputum production. Emphysema involves destruction of the alveolar walls, reducing the surface area available for gas exchange and causing airflow limitation.

Clinical Findings

1. Spirometry Results: Consistent with obstructive pulmonary disease due to decreased FEV1/FVC ratio. Most likely pulmonary diagnosis: COPD.

2. Subjective Findings:

– Chronic cough with sputum production
– Dyspnea on exertion
– History of smoking

3. Objective Findings:

– Decreased breath sounds on auscultation
– Increased anteroposterior diameter of the chest (barrel chest)
– Increased residual volume on pulmonary function tests

Management of COPD

Disease Severity:

The patient’s disease severity can be classified as moderate based on their symptoms and spirometry results. It is considered stable at the current presentation.

Medication Classes:

1. Bronchodilators (e.g., Albuterol): These medications are recommended as first-line treatment for COPD to improve airflow by relaxing the smooth muscles of the airways.
2. Inhaled Corticosteroids (e.g., Fluticasone): Used in combination with bronchodilators for moderate to severe COPD to reduce inflammation and exacerbations.

Mechanism of Action:

– Bronchodilators: Stimulate beta-adrenergic receptors in the airways, leading to relaxation of bronchial smooth muscles and bronchodilation.
– Inhaled Corticosteroids: Reduce airway inflammation by inhibiting the production of inflammatory mediators.

Non-Pharmacological Treatments:

1. Pulmonary Rehabilitation: Includes exercise training, education, and psychosocial support to improve quality of life and functional capacity.
2. Oxygen Therapy: Supplemental oxygen is recommended for patients with severe COPD and chronic hypoxemia to improve oxygenation.

By implementing a comprehensive treatment plan that includes pharmacological and non-pharmacological interventions based on evidence-based guidelines, healthcare providers can effectively manage COPD and improve the patient’s quality of life while reducing the risk of exacerbations and disease progression.




This question has been answered.

Get Answer